Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain

Objective The treatment of iron deficiency (ID) with ferric carboxymaltose (FCM) improves the functional class and quality of life of chronic heart failure (CHF) patients with reduced left ventricular ejection fraction (LVEF), and reduces the rate of hospitalization due to worsening CHF. This study...

ver descrição completa

Detalhes bibliográficos
Autores: Delgado, JF, Oliva, J, Gonzalez-Franco, A, Cepeda, JM, Garcia-Garcia, JA, Gonzalez-Dominguez, A, Garcia-Casanovas, A, Merino, SJ, Comin-Colet, J
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2020
País:España
Recursos:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositório:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p10732
Acesso em linha:https://fisabio.portalinvestigacion.com/publicaciones/10732
Access Level:Acceso aberto
Palavra-chave:Budget impact
chronic heart failure
ferric carboxymaltose
heart failure
iron deficiency
id ES_86b986a776fc552a3b1fbe9fc8745773
oai_identifier_str oai:fisabio.fundanetsuite.com:p10732
network_acronym_str ES
network_name_str España
repository_id_str
spelling Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in SpainDelgado, JFOliva, JGonzalez-Franco, ACepeda, JMGarcia-Garcia, JAGonzalez-Dominguez, AGarcia-Casanovas, AMerino, SJComin-Colet, JBudget impactchronic heart failureferric carboxymaltoseheart failureiron deficiencyObjective The treatment of iron deficiency (ID) with ferric carboxymaltose (FCM) improves the functional class and quality of life of chronic heart failure (CHF) patients with reduced left ventricular ejection fraction (LVEF), and reduces the rate of hospitalization due to worsening CHF. This study aims to evaluate the budget impact for the Spanish National Health System (SNHS) of treating ID in reduced LVEF CHF with FCM compared to non-iron treatment. Methods We simulated a hypothetical cohort of 1000 CHF patients with ID and reduced LVEF based on the Spanish population characteristics. A decision-analytic model was also built using the data from the largest FCM clinical trial (CONFIRM-HF) that lasted for a year. We considered the use of healthcare resources from a national prospective study. A deterministic sensitivity analysis was carried out varying the corresponding baseline data by +/- 25%. Results The cost of treating the simulated population with FCM was euro2,570,914, while that of the non-iron treatment was euro3,105,711, which corresponds to a cost saving of euro534,797 per 1,000 patients in one year. Cost savings were mainly due to a decrease in the number of hospitalizations. All sensitivity analysis showed cost savings for the SNHS. Conclusions FCM results in an annual cost saving of euro534.80 per patient, and would thus be expected to reduce the economic burden of CHF in Spain.TAYLOR & FRANCIS LTD2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/10732JOURNAL OF MEDICAL ECONOMICSISSN: 13696998ISSNe: 1941837Xreponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p107322026-06-11T12:45:17Z
dc.title.none.fl_str_mv Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain
title Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain
spellingShingle Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain
Delgado, JF
Budget impact
chronic heart failure
ferric carboxymaltose
heart failure
iron deficiency
title_short Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain
title_full Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain
title_fullStr Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain
title_full_unstemmed Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain
title_sort Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain
dc.creator.none.fl_str_mv Delgado, JF
Oliva, J
Gonzalez-Franco, A
Cepeda, JM
Garcia-Garcia, JA
Gonzalez-Dominguez, A
Garcia-Casanovas, A
Merino, SJ
Comin-Colet, J
author Delgado, JF
author_facet Delgado, JF
Oliva, J
Gonzalez-Franco, A
Cepeda, JM
Garcia-Garcia, JA
Gonzalez-Dominguez, A
Garcia-Casanovas, A
Merino, SJ
Comin-Colet, J
author_role author
author2 Oliva, J
Gonzalez-Franco, A
Cepeda, JM
Garcia-Garcia, JA
Gonzalez-Dominguez, A
Garcia-Casanovas, A
Merino, SJ
Comin-Colet, J
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Budget impact
chronic heart failure
ferric carboxymaltose
heart failure
iron deficiency
topic Budget impact
chronic heart failure
ferric carboxymaltose
heart failure
iron deficiency
description Objective The treatment of iron deficiency (ID) with ferric carboxymaltose (FCM) improves the functional class and quality of life of chronic heart failure (CHF) patients with reduced left ventricular ejection fraction (LVEF), and reduces the rate of hospitalization due to worsening CHF. This study aims to evaluate the budget impact for the Spanish National Health System (SNHS) of treating ID in reduced LVEF CHF with FCM compared to non-iron treatment. Methods We simulated a hypothetical cohort of 1000 CHF patients with ID and reduced LVEF based on the Spanish population characteristics. A decision-analytic model was also built using the data from the largest FCM clinical trial (CONFIRM-HF) that lasted for a year. We considered the use of healthcare resources from a national prospective study. A deterministic sensitivity analysis was carried out varying the corresponding baseline data by +/- 25%. Results The cost of treating the simulated population with FCM was euro2,570,914, while that of the non-iron treatment was euro3,105,711, which corresponds to a cost saving of euro534,797 per 1,000 patients in one year. Cost savings were mainly due to a decrease in the number of hospitalizations. All sensitivity analysis showed cost savings for the SNHS. Conclusions FCM results in an annual cost saving of euro534.80 per patient, and would thus be expected to reduce the economic burden of CHF in Spain.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/10732
url https://fisabio.portalinvestigacion.com/publicaciones/10732
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv TAYLOR & FRANCIS LTD
publisher.none.fl_str_mv TAYLOR & FRANCIS LTD
dc.source.none.fl_str_mv JOURNAL OF MEDICAL ECONOMICS
ISSN: 13696998
ISSNe: 1941837X
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412394877321216
score 15,198674

Registros relacionados